Neurociencia del consumo y dependencia de sustancias psicoactivas
Neurociencia del consumo y dependencia de sustancias psicoactivas Neurociencia del consumo y dependencia de sustancias psicoactivas
6. TRASTORNOS CONCURRENTESKapur S, Mann JJ (1992) Role of the dopaminergic system in depression.Biological Psychiatry, 32:1–17.Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptorexplain the action of atypical antipsychotics: a new hypothesis. AmericanJournal of Psychiatry, 158:360–369.Kendler KS y colab. (1993) Smoking and major depression: a causal analysis.Archives of General Psychiatry, 50:36–43.Kenny PJ, Markou A (2001) Neurobiology of the nicotine withdrawal syndrome.Pharmacology, Biochemistry and Behavior, 70:531–549.Kessler RC y colab. (1994) Lifetime and 12-month prevalence of DSM-III-Rpsychiatric disorders in the United States: results from the National ComorbiditySurvey. Archives of General Psychiatry, 51:8–19.Kessler RC y colab. (1996) The epidemiology of co-occurring addictive andmental disorders: implications for prevention and service utilization. AmericanJournal of Orthopsychiatry, 66:17–31.Khantzian EJ (1985) The self-medication hypothesis of addictive disorders:focus on heroin and cocaine dependence. American Journal of Psychiatry,142:1259–1264.Khantzian EJ (1997) The self-medication hypothesis of substance use disorders:a reconsideration and recent applications. Harvard Review of Psychiatry,4:231–244.Kikuchi-Yorioka Y, Sawaguchi T (2000) Parallel visuospatial and audiospatialworking memory processes in the monkey dorsolateral prefrontal cortex. NatureReviews in Neuroscience, 3:1075–1076.Kilts CD y colab. (2001) Neural activity related to drug craving in cocaine addiction.Archives of General Psychiatry, 58:334–341.Knable MB, Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia.Journal of Psychopharmacology, 11:123–131.Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function ofreward pathways. Trends in Pharmacological Sciences, 13:177–184.Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, andallostasis. Neuropsychopharmacology, 24:97–129.Koob GF, Wall TL, Bloom FE (1989) Nucleus accumbens as a substrate for theaversive stimulus effects of opiate withdrawal. Psychopharmacology, 98:530–534.Koob GF y colab. (1993) Opponent process and drug dependence: neurobiologicalmechanisms. Seminars in Neuroscience, 5:351–358.Kosten TR, Ziedonis DM (1997) Substance abuse and schizophrenia: editors’introduction. Schizophrenia Bulletin, 23:181–186.Kosten TR, Markou A, Koob GF (1998) Depression and stimulant dependence:neurobiology and pharmacotherapy. Journal of Nervous and Mental Disorders,186:737–745.Krystal JH y colab. (1999) Toward a rational pharmacotherapy of comorbid substanceabuse in schizophrenic patients. Schizophrenia Research, 35(Suppl.):S35–S49.199
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASLahti AC y colab. (1995) Subanesthetic doses of ketamine stimulate psychosis inschizophrenia. Neuropsychopharmacology, 13:9–19.Lam RW y colab. (1996) Effects of rapid tryptophan depletion in patients withseasonal affective disorder in remission after light therapy. Archives of GeneralPsychiatry, 53:41–44.Latimer WW y colab. (2002) Gender differences in psychiatric comorbidityamong adolescents with substance use disorders. Experimental & ClinicalPsychopharmacology, 10:310-315.Le Duc PA, Mittleman G (1995) Schizophrenia and psychostimulant abuse: areview and re-analysis of clinical evidence. Psychopharmacology, 121:407–427.Legault M, Rompre PP, Wise RA (2000) Chemical stimulation of the ventralhippocampus elevates nucleus accumbens dopamine by activating dopaminergicneurons of the ventral tegmental area. Journal of Neuroscience, 20:1635–1642.Liljequist S (1991) NMDA receptor antagonists inhibit ethanol-produced locomotorstimulation in NMRI mice. Alcohol, 8:309–312.Lima L, Salazar M, Trejo E (1993) Modulation of 5-HTIA receptors in the hippocampusand the raphe area of rats treated with clonazepam. Progress inNeuropsychopharmacology and Biological Psychiatry, 17:663–677.Lloyd KG, Thuret F, Pilc A (1985) Upregulation of gamma-aminobutyric acid(GABA) B binding sites in rat frontal cortex: a common action of repeatedadministration of different classes of antidepressants and electroshock. Journal ofPharmacology and Experimental Therapeutics, 235:191–199.Lloyd KG y colab. (1989) The GABAergic hypothesis of depression. Progress inNeuropsychopharmacology and Biological Psychiatry, 13:341–351.Lodge D, Johnson KM (1990) Noncompetitive excitatory amino acid receptorantagonists. Trends in Pharmacological Sciences, 11:81–86.Luisada PV (1978) The phencyclidine psychosis: phenomenology and treatment.NIDA Research Monograph, 21:241–253.Lysaker P y colab. (1994) Relationship of positive and negative symptoms tococaine abuse in schizophrenia. Journal of Nervous and Mental Disorders,182:109–112.McEvoy JP, Freudenreich O, Wilson WH (1999) Smoking and therapeuticresponse to clozapine in patients with schizophrenia. Biological Psychiatry,46:125–129.McEvoy J y colab. (1995) Clozapine decreases smoking in patients with chronicschizophrenia. Biological Psychiatry, 37:550–552.McGrath PJ y colab. (1996) Imipramine treatment of alcoholics with primary depression:a placebo-controlled clinical trial. Archives of General Psychiatry, 53:232–240.Malhotra AK y colab. (1997) Ketamine-induced exacerbation of psychoticsymptoms and cognitive impairment in neuroleptic-free schizophrenics.Neuropsychopharmacology, 17:141–150.Manoach DS y colab. (2000) Schizophrenic subjects show aberrant fMRI activationof dorsolateral prefrontal cortex and basal ganglia during working memoryperformance. Biological Psychiatry, 48:99–109.200
- Page 170 and 171: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 172 and 173: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 174 and 175: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 176 and 177: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 178 and 179: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 180 and 181: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 182 and 183: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 184 and 185: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 186 and 187: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 188 and 189: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 190 and 191: Capítulo 6Trastornos ConcurrentesI
- Page 192 and 193: 6. TRASTORNOS CONCURRENTES3. El uso
- Page 194 and 195: 6. TRASTORNOS CONCURRENTESy Meador-
- Page 196 and 197: 6. TRASTORNOS CONCURRENTESprobablem
- Page 198 and 199: 6. TRASTORNOS CONCURRENTESde drogas
- Page 200 and 201: 6. TRASTORNOS CONCURRENTESy Turski,
- Page 202 and 203: 6. TRASTORNOS CONCURRENTESEl víncu
- Page 204 and 205: 6. TRASTORNOS CONCURRENTESAlcohol y
- Page 206 and 207: 6. TRASTORNOS CONCURRENTESSerotonin
- Page 208 and 209: 6. TRASTORNOS CONCURRENTESFunción
- Page 210 and 211: 6. TRASTORNOS CONCURRENTESRECUADRO
- Page 212 and 213: 6. TRASTORNOS CONCURRENTEStos psiqu
- Page 214 and 215: 6. TRASTORNOS CONCURRENTESCarol G y
- Page 216 and 217: 6. TRASTORNOS CONCURRENTESdepressio
- Page 218 and 219: 6. TRASTORNOS CONCURRENTESHall RG y
- Page 222 and 223: 6. TRASTORNOS CONCURRENTESMansvelde
- Page 224 and 225: 6. TRASTORNOS CONCURRENTESPetty F (
- Page 226 and 227: 6. TRASTORNOS CONCURRENTESSevy S y
- Page 228: 6. TRASTORNOS CONCURRENTESlesions o
- Page 231 and 232: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 233 and 234: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 235 and 236: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 237 and 238: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 239 and 240: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 241 and 242: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 243 and 244: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 245 and 246: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 247 and 248: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 249 and 250: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 251 and 252: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 253 and 254: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 255 and 256: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 257 and 258: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 259 and 260: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 261 and 262: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 263 and 264: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 265 and 266: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 267 and 268: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 269 and 270: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
6. TRASTORNOS CONCURRENTESKapur S, Mann JJ (1992) Role of the dopaminergic system in <strong>de</strong>pression.Biological Psychiatry, 32:1–17.Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptorexplain the action of atypical antipsychotics: a new hypothesis. AmericanJournal of Psychiatry, 158:360–369.Kendler KS y colab. (1993) Smoking and major <strong>de</strong>pression: a causal analysis.Archives of General Psychiatry, 50:36–43.Kenny PJ, Markou A (2001) Neurobiology of the nicotine withdrawal syndrome.Pharmacology, Biochemistry and Behavior, 70:531–549.Kessler RC y colab. (1994) Lifetime and 12-month prevalence of DSM-III-Rpsychiatric disor<strong>de</strong>rs in the United States: results from the National ComorbiditySurvey. Archives of General Psychiatry, 51:8–19.Kessler RC y colab. (1996) The epi<strong>de</strong>miology of co-occurring addictive andmental disor<strong>de</strong>rs: implications for prevention and service utilization. AmericanJournal of Orthopsychiatry, 66:17–31.Khantzian EJ (1985) The self-medication hypothesis of addictive disor<strong>de</strong>rs:focus on heroin and cocaine <strong>de</strong>pen<strong>de</strong>nce. American Journal of Psychiatry,142:1259–1264.Khantzian EJ (1997) The self-medication hypothesis of substance use disor<strong>de</strong>rs:a reconsi<strong>de</strong>ration and recent applications. Harvard Review of Psychiatry,4:231–244.Kikuchi-Yorioka Y, Sawaguchi T (2000) Parallel visuospatial and audiospatialworking memory processes in the monkey dorsolateral prefrontal cortex. NatureReviews in Neuroscience, 3:1075–1076.Kilts CD y colab. (2001) Neural activity related to drug craving in cocaine addiction.Archives of General Psychiatry, 58:334–341.Knable MB, Weinberger DR (1997) Dopamine, the prefrontal cortex and schizophrenia.Journal of Psychopharmacology, 11:123–131.Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function ofreward pathways. Trends in Pharmacological Sciences, 13:177–184.Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, andallostasis. Neuropsychopharmacology, 24:97–129.Koob GF, Wall TL, Bloom FE (1989) Nucleus accumbens as a substrate for theaversive stimulus effects of opiate withdrawal. Psychopharmacology, 98:530–534.Koob GF y colab. (1993) Opponent process and drug <strong>de</strong>pen<strong>de</strong>nce: neurobiologicalmechanisms. Seminars in Neuroscience, 5:351–358.Kosten TR, Ziedonis DM (1997) Substance abuse and schizophrenia: editors’introduction. Schizophrenia Bulletin, 23:181–186.Kosten TR, Markou A, Koob GF (1998) Depression and stimulant <strong>de</strong>pen<strong>de</strong>nce:neurobiology and pharmacotherapy. Journal of Nervous and Mental Disor<strong>de</strong>rs,186:737–745.Krystal JH y colab. (1999) Toward a rational pharmacotherapy of comorbid substanceabuse in schizophrenic patients. Schizophrenia Research, 35(Suppl.):S35–S49.199
Change language